June 2019

Certara Announces First Recipients of Certara-Monash University Industry Drug Development Fellowships

2019 年 6 月 25 日

PRINCETON, NJ – 2019 年 6 月 25 日 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, and Monash University today announced the recipients of the inaugural Certara-Monash University Industry Drug Development Fellowships – Dr. Katrina Hui, Dr. Yu-Wei Lin, and Dr. Zheng Liu.

Population Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Paediatric Population

2019 年 6 月 24 日

By webdev

Pharmacodynamics of rituximab on B cells in paediatric post-HSCT patients with EBV

2019 年 6 月 24 日

By webdev

Investigating Impacts of Model Parameters Correlations in Global Sensitivity Analysis: Determining the Most Influential Parameters of a Minimal PBPK Model of Midazolam

2019 年 6 月 24 日

By webdev

Development and Performance Evaluation of a semi-mechanistic PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eye

2019 年 6 月 24 日

By webdev

Transporter inhibition: modelling in-vitro Transwell Assays

2019 年 6 月 24 日

By webdev

Development of Paclitaxel PBPK Model to Predict Tumour Concentration in Cancer Patients

2019 年 6 月 24 日

By webdev

Mechanistic models of cancer Mechanistic models cancer-immune cycle and immunotherapies

2019 年 6 月 24 日

By webdev

Integration of a Tumour Growth Inhibition Model within a Mouse Physiologically-Based Pharmacokinetic Model

2019 年 6 月 24 日

By webdev

Optimize Immuno-oncology Drug Discovery and Development Using QSP

2019 年 6 月 19 日

By webdev

A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to better predict effective drug combinations, especially to more accurately correlate the physiological differences between preclinical models and human patients.

1 页，共 2 页

Month: June 2019